Attributable costs of central line–associated bloodstream infections in a pediatric hematology/oncology population

Bacterial bloodstream infections in the allogeneic hematopoietic cell transplant patient: new considerations for a persistent nemesis

“…In addition, patients with CLABSI had length of stay that were 21.2 days longer than those without CLABSI (P o 0.0001). 6 …”

“…Abbreviations: BSI = bloodstream infection; CLABSI = central line-associated bloodstream infection; ICU = intensive care unit; IQR = interquartile range; MBI-LCBI = mucosal barrier injury laboratory-confirmed bloodstream infection. Adapted from Dandoy et al 6 Retrospective review of 374 consecutive pediatric hematopoietic cell transplants, in which 100 patients developed at least one infection (170 infections analyzed).…”

“…145 A recent evaluation in pediatric HCT and oncology patients with ambulatory BSIs demonstrated a $40 852 median hospital charge with room, pharmacy and procedure charges accounting for more than 70% of total charges. 146 Finally, Wilson et al 6 utilized propensity scoring with matched cases while controlling for other covariates and defined the attributable cost of CLABSI to approximate $70 000 per BSI event in pediatric hematology oncology patients. In addition, patients with CLABSI had length of stay that were 21.2 days longer than those without CLABSI (P o 0.0001).…”

“…[4][5][6] Central line-associated bloodstream infections (CLABSIs) are serious complications in HCT recipients and lead to prolonged hospitalization, and intensive care admissions. [4][5][6][7] According to National Healthcare Safety Network (NHSN) data, CLABSI incidence continues to be highest in the HCT population, wherein rates are higher than in any other high-risk population, including solid organ transplant and burn patients, or care setting (that is, intensive care units). 8 This paper will review the impact of bacterial BSI in the current transplant period as measured by resource utilization and associated morbidity and mortality in allo-HCT patients.…”

What is the right approach to infection prevention and control for children living at home with invasive devices?

“…(21)(22)(23) The implications for health services are also significant: it costs almost $70,000 to treat a central line infection in a child. (24,25) Yet the rise of homecare for children with complex medical needs has not been accompanied by a parallel rise in the recognition of these risks, nor in the development of strategies to mitigate them. (26)(27)(28)(29) How best families and children can be supported in in preventing and controlling infection in the community remains poorly understood…”